CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

Discover why CLLS is a top speculative Buy, with promising CAR-T therapies, strong big pharma partnerships, and attractive ...

These companies could innovate their way to success.

CRISPR Therapeutics recently drew attention as updates highlighted progress in its gene-editing pipeline, including early-stage studies of CTX310, an in vivo therapy designed to lower LDL cholesterol ...

Key opportunities in the market include leveraging CRISPR's precision for improved crop traits, meeting food security demands amid climate change, and sustainable agriculture trendsDublin, Dec. 09, ...

Now, it’s worth noting Stock Advisor's total average return is 991% — a market-crushing outperformance compared to 195% for ...

Credo stock is now up more than 180% so far this year, demonstrating that there are outstanding opportunities for investors ...

Dyadic International, Inc. ( DYAI) IAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 December 9, 2025 9:30 AM EST Good day, and welcome to the iAcessAlpha Virtual Best Ideas winter ...

Given the potential for a sizable sell-off, it makes sense for investors to move to S&P 500 Dividend Aristocrat stocks like ...

As giant companies, especially in technology, propel the S&P 500 to new heights, a select group of mid-sized companies are ...

For the week ending December 5, the Russell 2000 index rose by 1.58%. This gain was higher than the 0.85% rise seen in the broad S&P 500 index during the same time. Small-cap stocks have also recently ...

Six new members and three promoted vice-presidents are set to join the European Research Council (ERC) scientific council at ...